prosetin
(2)
ProJenX
ProJenX is a New York City clinical-stage biotechnology company developing prosetin, a first-in-class, oral, brain-penetrant MAP4K inhibitor for amyotrophic lateral sclerosis (ALS) and other neurodegenerative brain diseases. Spun out of a two-decade collaboration between the nonprofit Project ALS and Columbia University researchers, ProJenX is built on the discovery that inhibiting MAP4 kinases protects motor neurons across multiple patient-derived stem cell models of ALS. The company is running the PRO-101 Phase 1b trial in people living with ALS.
Stan Abel
Stan Abel is President and CEO of ProJenX, a clinical-stage biotech spun out of Columbia University research and Project ALS, racing to get its lead drug prosetin - an oral MAP4K inhibitor - into ALS patients after two decades of laboratory work and a $15 million Series A.